医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PharmaEngine and Merrimack Amend MM-398 License Agreement

2014年09月26日 PM05:56
このエントリーをはてなブックマークに追加


 

TAIPEI, Taiwan

PharmaEngine, Inc. (TWO: 4162), announced today that the company has signed an Amendment to its License Agreement of MM-398 (aka PEP02, nanoliposomal irinotecan injection, nal-IRI) with Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK). This week Merrimack announced an exclusive license and collaboration agreement with Baxter International Inc. (NYSE: BAX) for MM-398 outside of the United States and Taiwan. PharmaEngine licensed the development, manufacturing and commercialization rights of PEP02 in Asia and Europe to Merrimack for US$220 million plus royalties and sublicense revenue in May 2011. In May 2014, the companies announced the successful completion of a global phase III study in patients with metastatic pancreatic cancer previously treated with gemcitabine-based therapy.

Under the amendment, PharmaEngine will receive an immediate payment of US$7 million and a guaranteed payment of US$5 million upon the acceptance of the MM-398 New Drug Application by the U.S. Food and Drug Administration (FDA) or no later than April 30, 2015. This payment was previously contingent on Merrimack receiving certain regulatory designations from the FDA for MM-398. Additionally, the amendment accelerates the reduction in the percentage of sublicense revenue to be received by PharmaEngine for future regulatory and approval milestones resulting in maximum sublicense revenue of US$39.5 million. On the other hand, PharmaEngine is excluded from receiving sublicense revenue related to Merrimack’s upfront payment and up to US$150 million in development milestone payments from Baxter. The remaining US$200 million of regulatory and sales milestones, as well as the tiered royalties, remain unchanged. In sum, PharmaEngine is eligible to receive up to a total of $251.5 million in the future, in addition to the license fees of US$15 million that were previously received under the Agreement.

“We are pleased that the amended terms facilitated Merrimack to close their deal with Baxter who expects to apply for regulatory approvals outside of the US beginning in 2015,” said Grace Yeh, Ph.D., President and Chief Executive Officer. “This win-win partnership provided PharmaEngine with short term cash payments of $12 million; mid-term investment of additional clinical trials by the two partners; and long-term upside of market access by Baxter which has global presence in the healthcare industry.”

About PharmaEngine, Inc. (TWO: 4162)

PharmaEngine is a biopharmaceutical company established in Taipei, Taiwan in 2003. PharmaEngine focuses on the development of new drugs for the treatment of cancer and Asian prevalent diseases. PharmaEngine has three projects, two in clinical development (PEP02 / MM-398 and PEP503 / NBTXR3) and one in drug discovery (PEP06). For further information, please visit PharmaEngine’s website at http://www.pharmaengine.com.

CONTACT

PharmaEngine, Inc.
Peter Wu, +886-2-2515-8228 ext. 300
Director,
Corporate Development
peter.wu@pharmaengine.com
Mobile:
+886-935-154-559

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田在美国临床肿瘤学会(ASCO)和欧洲血液学会(EHA)年会上重点介绍其强大的肿瘤产品阵容和后续产品线数据
  • AVITA Medical Announces Presentation at ISPOR Meeting Validating Acute Burn Health Economic Model
  • GRAIL Announces $300 Million Raised in Oversubscribed Series C Financing
  • GRAIL(思为诺)宣布完成3亿美元C轮融资获超额认购
  • レスメド後援の研究で在宅酸素療法と在宅非侵襲的換気療法の併用が費用対効果の高いCOPD治療法であると判明